Anticholinesterase drugs
anticholinesterase drugs mechanism classification neostigmine physostigmine organophosphate

This composite educational graphic details the neurobiological effects of physostigmine during emotion-recognition tasks in Bipolar Disorder (BD) and Healthy Controls (HC). The image is organized into three comparative panels (A, B, C), each containing a functional MRI (fMRI) brain scan and corresponding behavioral dot plots for accuracy and reaction time. Panel A shows sagittal brain activation where physostigmine increases activity in the right superior frontal gyrus (Brodmann Area 46) in BD patients compared to placebo. Panel B illustrates decreased activation in the left anterior cingulate cortex (BA32) in healthy controls following physostigmine administration relative to placebo. Panel C displays a direct contrast between the two groups under physostigmine influence, highlighting increased activation in the bilateral posterior/dorsal cingulate cortex (BA31) in BD patients relative to controls. The behavioral data plots indicate that while neurofunctional activation patterns shifted significantly (p<0.05), behavioral performance regarding recognition accuracy and reaction times remained largely unchanged across groups. This material illustrates the differential cholinergic impact on frontocingulate circuits involved in emotional processing and top-down regulation in mood disorders.

A comparison of two anteroposterior (AP) erect abdominal X-rays demonstrating the radiological management of acute colonic pseudo-obstruction (Ogilvie's syndrome). The 'Before Neostigmine' image shows marked gaseous distention of the large and small bowel loops throughout the abdominal cavity, with prominent multiple air-fluid levels indicative of functional bowel obstruction. The 'After Neostigmine' image shows a significant reduction in bowel loop caliber and a decrease in the number and height of air-fluid levels, indicating successful pharmacological decompression. In the second image, a radiopaque nasogastric (NG) tube is visible, coursing from the upper midline into the left upper quadrant, terminating in the stomach for decompression. Additional monitoring leads are visible on the periphery. This comparison illustrates the clinical effectiveness of neostigmine, an acetylcholinesterase inhibitor, in restoring bowel motility and reducing intraluminal pressure in cases of pseudo-obstruction.
![This pathophysiology diagram illustrates the mechanism of pH-induced physiological drug resistance (PIPDR) and its circumvention via nanoparticle (NP) delivery. The diagram is divided into two clinical scenarios: normal tissue and tumor tissue. In normal tissue (extracellular pH 7.4), weakly basic drugs exist in uncharged forms and freely permeate the cell membrane to enter normal cells (intracellular pH 7.0–7.4). In the tumor microenvironment (extracellular pH 6.5–7.0), the acidic conditions cause the drug molecules to become protonated ([HD]+). These protonated forms are depicted as clustered aggregates with reduced membrane permeability, leading to decreased intracellular drug concentration in tumor cells. The lower section demonstrates the educational concept of NP-mediated delivery: drug-loaded nanoparticles enter tumor cells through endocytosis, bypassing pH-dependent membrane permeability barriers. Once inside the intracellular environment (pH 7.0–7.4), the drugs are released in their active, uncharged forms, effectively restoring therapeutic efficacy. The diagram uses color-coded arrows and chemical equilibrium equations to highlight how local pH gradients influence pharmacokinetics and how nanomedicine can overcome extracellular acidity-induced resistance.](/_next/image?url=https%3A%2F%2Fcdn.orris.care%2Fcdss_images%2Fpmc_clinical_VQA_c30d6d3413fb487b9b65ce7badf6c1f2b097f8647263f82b5d6f9482aee245ab.jpg&w=3840&q=75)
This pathophysiology diagram illustrates the mechanism of pH-induced physiological drug resistance (PIPDR) and its circumvention via nanoparticle (NP) delivery. The diagram is divided into two clinical scenarios: normal tissue and tumor tissue. In normal tissue (extracellular pH 7.4), weakly basic drugs exist in uncharged forms and freely permeate the cell membrane to enter normal cells (intracellular pH 7.0–7.4). In the tumor microenvironment (extracellular pH 6.5–7.0), the acidic conditions cause the drug molecules to become protonated ([HD]+). These protonated forms are depicted as clustered aggregates with reduced membrane permeability, leading to decreased intracellular drug concentration in tumor cells. The lower section demonstrates the educational concept of NP-mediated delivery: drug-loaded nanoparticles enter tumor cells through endocytosis, bypassing pH-dependent membrane permeability barriers. Once inside the intracellular environment (pH 7.0–7.4), the drugs are released in their active, uncharged forms, effectively restoring therapeutic efficacy. The diagram uses color-coded arrows and chemical equilibrium equations to highlight how local pH gradients influence pharmacokinetics and how nanomedicine can overcome extracellular acidity-induced resistance.

A pathophysiology diagram illustrating three primary mechanisms of azole drug resistance in Aspergillus fumigatus. Mechanism A (Reduced azole affinity) shows a brown cyp51A gene with lightning bolt symbols representing single amino acid substitutions (G54, P216, F219, M220, G448), resulting in mutated CYP51A enzymes that cannot bind azole drugs. Mechanism B (Overexpression of CYP51A) depicts a green cyp51A gene with a TR34/L98H mutation in the promoter region, leading to increased mRNA transcription and a high concentration of target enzymes. Mechanism C (Overexpression of efflux transporter) illustrates multiple blue cylindrical Cdr1B transporters embedded in the cell membrane, using blue arrows to show the active expulsion of azole drugs (represented by brown triangles) from the intracellular space. This medical illustration provides a clear visual summary of genetic mutations and protein overexpression strategies used by fungal pathogens to evade antifungal treatments targeting the ergosterol synthesis pathway.

Anticholinesterase Drugs
├── Reversible
│ ├── Short-acting: Edrophonium
│ ├── Intermediate-acting: Physostigmine, Neostigmine, Pyridostigmine, Rivastigmine, Donepezil, Galantamine
│ └── Long-acting (but reversible): Organophosphate-based ophthalmic agents (some)
└── Irreversible
└── Organophosphates: Echothiophate, Parathion, Malathion, Nerve agents (Sarin, Soman, VX)

| Drug | Selectivity | Duration | Notes |
|---|---|---|---|
| Donepezil | AChE > BuChE | Long (t½ ~70 hrs) | First-line; once daily; all stages of AD |
| Rivastigmine | AChE + BuChE | Intermediate | Oral/patch; also for Parkinson's dementia |
| Galantamine | AChE + allosteric nicotinic modulator | Intermediate | Also enhances nicotinic receptor sensitivity |
| Tacrine | AChE + BuChE | Short | Withdrawn (hepatotoxicity) |

| System | Effect |
|---|---|
| Salivation | Increased |
| Lacrimation | Increased |
| Urination | Increased (detrusor contraction) |
| Defecation / Diarrhea | Increased GI motility |
| GI cramps | Nausea, vomiting |
| Emesis | Nausea/vomiting |
| Eye | Miosis, blurred vision |
| Heart | Bradycardia, heart block |
| Bronchi | Bronchoconstriction, increased secretions |
| BP | Hypotension |
| Sweat glands | Diaphoresis |
| Indication | Drug(s) of Choice |
|---|---|
| Myasthenia gravis (chronic) | Pyridostigmine (oral), neostigmine |
| Myasthenia gravis (diagnosis) | Edrophonium (historical), anti-AChR antibodies now preferred |
| Reversal of NMB (non-depolarizing) | Neostigmine + glycopyrrolate/atropine |
| Alzheimer's dementia | Donepezil, rivastigmine, galantamine |
| Anticholinergic overdose | Physostigmine (crosses BBB) |
| Glaucoma (open-angle) | Pilocarpine (direct); echothiophate (historical, withdrawn) |
| Paralytic ileus / urinary retention | Neostigmine |
| Ogilvie's syndrome | Neostigmine IV |
| Feature | Physostigmine | Neostigmine |
|---|---|---|
| Structure | Tertiary amine (natural) | Quaternary amine (synthetic) |
| BBB penetration | Yes | No |
| GI absorption | Good | Poor |
| CNS effects | Yes | No |
| Skeletal muscle effect | Moderate | Greater |
| Main uses | Anticholinergic OD reversal, glaucoma | NMB reversal, MG, ileus |
| Atropine reversal | Yes (peripheral + some CNS) | Yes (peripheral only) |
Refer from kd tripathi and other resources which have easy language and understanding which we could write in our exams and can get good marks
cholinergic crisis SLUDGE symptoms organophosphate poisoning muscarinic nicotinic

This pathophysiology diagram illustrates the neurotoxic mechanisms of organophosphates (OPs) and their potential link to dissociative disorders. The visual is divided into two primary sections. The left panel depicts the cholinergic damage pathway, showing how OPs inhibit acetylcholinesterase (AChE), the enzyme responsible for breaking down acetylcholine into choline. This inhibition results in high concentrations of acetylcholine, leading to the overstimulation of nicotinic and muscarinic receptors. The downstream consequence is neuronal death within the hypothalamus, thalamus, and basal anterior cerebral cortex. The right panel focuses on non-cholinergic neurotoxicity, where OPs cause direct injury to the serotonergic (red) and dopaminergic (blue) pathways, visualized on a sagittal brain section. Both pathways converge at the bottom of the diagram, suggesting that combined cholinergic, serotonergic, and dopaminergic damage may serve as a pathophysiological substrate for the development of dissociative disorders. The diagram utilizes chemical structures, receptor icons, and anatomical brain maps to synthesize complex biochemical and neurological interactions in the context of pesticide exposure.

This medical illustration comprises six sagittal-view diagrams of the human brain (a–f) detailing cholinergic pathways and the distribution of muscarinic receptor subtypes (M1–M5). Diagram (a) maps primary cholinergic inputs, illustrating projections from basal forebrain nuclei, including the medial septum (MS), diagonal band of Broca (DB), and nucleus basalis magnocellularis (nBM), toward the neocortex (frontal, parietal, occipital), amygdala (AMY), and hippocampus (Hc). Brainstem cholinergic projections from the pedunculopontine nucleus (PPN) and laterodorsal tegmentum (LDT) are shown targeting the thalamus and basal forebrain. Panels (b) through (f) utilize color-coded heatmaps to indicate the expression density of muscarinic receptor subtypes: M1 (purple) and M2 (green) show high cortical and hippocampal density; M3 (yellow) is localized primarily in the cortex and basal ganglia; M4 (red) exhibits strong expression in the striatum and neocortex; and M5 (cyan) displays more localized expression in the ventral tegmental area and substantia nigra. These diagrams facilitate understanding of cholinergic neurotransmission relevant to neurodegenerative diseases, epilepsy, and schizophrenia.

This composite diagnostic image consists of six phosphorimage autoradiograms (A–F) displaying mRNA expression patterns of nicotinic and muscarinic acetylcholine receptor subunits in avian brain sections. Panels A, B, E, and F illustrate nicotinic subunits (CHRNA5, CHRNA7, CHRNA2, and CHRNA2/4 respectively), while panels C and D show muscarinic subunits (CHRM4 and CHRM2). Each panel demonstrates differential signal intensities in grayscale, where darker regions indicate higher gene expression. Black arrows across all panels point to the nucleus HVC (High Vocal Center) in the caudo-dorsal nidopallium, showing notable enrichment for CHRNA5 and CHRM4. Black arrowheads identify the location of Area X in the striatum, which shows particularly intense signal for CHRM4 (panel C) and CHRM2 (panel D). The autoradiograms provide a comparative visualization of neurochemical specializations within the song system, highlighting how specific receptor subunits are localized to different functional nuclei involved in vocal learning and motor control. Scale bar: 1 mm.
Note: KD Tripathi is not in the digital library, but the following is written in the same concise, point-by-point style KD Tripathi is known for, sourced from Lippincott Pharmacology, Katzung, and Goodman & Gilman.
ANTICHOLINESTERASE DRUGS
│
├── A. REVERSIBLE
│ ├── 1. Short-acting (minutes)
│ │ Edrophonium (10–20 min)
│ │
│ ├── 2. Intermediate-acting (hours)
│ │ Physostigmine (30 min – 2 hrs) ← tertiary amine
│ │ Neostigmine (30 min – 2 hrs) ← quaternary amine
│ │ Pyridostigmine (3–6 hrs) ← quaternary amine
│ │ Ambenonium
│ │
│ └── 3. Long-acting (used in Alzheimer's)
│ Donepezil, Rivastigmine, Galantamine, Tacrine (withdrawn)
│
└── B. IRREVERSIBLE
Organophosphates:
Echothiophate (ophthalmic)
Parathion, Malathion (insecticides)
Sarin, Soman, VX, Tabun (nerve agents / chemical warfare)

| Letter | Effect |
|---|---|
| S | Salivation increased |
| L | Lacrimation increased |
| U | Urination (detrusor contracts) |
| D | Defecation / Diarrhea |
| G | GI cramps |
| E | Emesis (nausea/vomiting) |

Key exam point: Quaternary amines (neostigmine, pyridostigmine, edrophonium) do NOT cross the BBB → no CNS effects. Tertiary amines (physostigmine) and organophosphates DO cross the BBB → CNS effects occur.
| Feature | Details |
|---|---|
| Type | Quaternary amine, short-acting |
| Mechanism | Electrostatic binding to anionic site of AChE (no covalent bond) |
| Duration | 10-20 minutes (rapidly excreted by kidney) |
| BBB? | NO |
| Uses | Diagnosis of myasthenia gravis (Tensilon test - historically); distinguishing myasthenic crisis from cholinergic crisis |
| Note | Now removed from market; anti-AChR antibody test is preferred |
| Feature | Details |
|---|---|
| Source | Natural alkaloid (Calabar bean) |
| Type | Tertiary amine - crosses BBB |
| Mechanism | Carbamylates esteratic site of AChE (reversible) |
| Duration | 30 min - 2 hrs |
| BBB? | YES (most important feature) |
Exam tip: "Physostigmine crosses the BBB - so it is used to reverse CNS effects of atropine poisoning. Neostigmine does NOT cross BBB and therefore cannot reverse CNS effects."
| Feature | Details |
|---|---|
| Type | Quaternary amine (synthetic) |
| Mechanism | Carbamylates AChE (reversible) |
| Duration | 30 min - 2 hrs |
| BBB? | NO |
| GI absorption | Poor (given parenterally or large oral doses) |
| Drug | Special Feature |
|---|---|
| Donepezil | Once daily (t½ = 70 hrs); mild-moderate-severe AD; well tolerated |
| Rivastigmine | Inhibits both AChE + BuChE; also for Parkinson's dementia; available as transdermal patch |
| Galantamine | Also acts as allosteric nicotinic receptor modulator (unique) |
| Tacrine | First agent; WITHDRAWN due to hepatotoxicity |
Exam tip: "None of these drugs stop the progression of Alzheimer's - they only delay it and give modest symptomatic benefit."

| System | Signs |
|---|---|
| Eye | Miosis (pin-point pupils), blurred vision |
| GI | Nausea, vomiting, diarrhea, cramps, defecation |
| Glands | Salivation, lacrimation, sweating (diaphoresis) |
| Respiratory | Bronchoconstriction + excessive secretions → respiratory failure |
| Heart | Bradycardia, hypotension |
| NMJ | Fasciculations → weakness → paralysis of respiratory muscles |
| CNS | Anxiety → seizures → coma (with organophosphates) |
Most common cause of death = RESPIRATORY FAILURE (bronchospasm + paralysis of diaphragm + CNS depression)
| Feature | Physostigmine | Neostigmine |
|---|---|---|
| Source | Natural (Calabar bean) | Synthetic |
| Chemical type | Tertiary amine | Quaternary amine |
| Crosses BBB? | YES | NO |
| GI absorption | Good | Poor |
| CNS effects | Yes | No |
| Effect on skeletal muscle | Moderate | Greater |
| Used for anticholinergic OD? | YES (can reverse CNS effects) | NO |
| Used in myasthenia gravis? | Not preferred | YES |
| Used for NMJ reversal? | No | YES |
| Clinical Use | Drug of Choice |
|---|---|
| Myasthenia gravis (chronic) | Pyridostigmine (oral) |
| Myasthenia gravis (acute/diagnosis) | Edrophonium (historical) / Neostigmine |
| Reversal of non-depolarizing NMB | Neostigmine + atropine |
| Alzheimer's disease | Donepezil (1st choice), Rivastigmine, Galantamine |
| Atropine/anticholinergic overdose | Physostigmine (crosses BBB) |
| Paralytic ileus / urinary retention | Neostigmine |
| Glaucoma (open angle) | Pilocarpine (direct); Echothiophate (historical) |
| Organophosphate poisoning | Atropine + Pralidoxime + Diazepam |
| Parkinson's dementia | Rivastigmine |
Explain me this topic im very new to this i cant understand whats happening
Nerve → releases ACh → ACh lands on organ → message delivered
↓
AChE comes and DESTROYS ACh
↓
Message stops. System resets.

| Receptor | Where | Effect when ACh lands |
|---|---|---|
| Muscarinic | Heart, smooth muscle (gut, lungs, bladder), glands, eyes | Slows heart, increases secretions, contracts gut, constricts pupil |
| Nicotinic | Skeletal muscle (NMJ), autonomic ganglia | Contracts muscles |
| S | Salivation — mouth fills with saliva |
|---|---|
| L | Lacrimation — tears pouring out |
| U | Urination — can't hold urine |
| D | Defecation / Diarrhea — loose stools |
| G | GI cramps — stomach pain |
| E | Emesis — nausea and vomiting |

| Drug | What it does |
|---|---|
| Atropine (high doses) | Blocks muscarinic receptors — stops the SLUDGE effects, opens the airways, raises heart rate. This is the LIFE-SAVING step. |
| Pralidoxime (2-PAM) | "Reactivates" AChE — pulls the organophosphate off the enzyme. Works ONLY if given early, before "aging" happens. |
| Diazepam | Stops the seizures |
NERVE releases ACh
↓
ACh crosses synapse
↓
ACh binds to receptor → EFFECT (heart slows, muscle contracts, etc.)
↓
AChE breaks down ACh → effect stops
===================================
GIVE ANTICHOLINESTERASE DRUG:
↓
AChE is BLOCKED → ACh is NOT broken down
↓
ACh piles up → PROLONGED and EXAGGERATED EFFECTS
(SLUDGE + muscle fasciculations/paralysis + CNS effects)
Try again
What was wrong with the last explanation? What do you want me to change? · What is your background right now?
Whats the use of these drugs
| Use | Drug |
|---|---|
| Myasthenia gravis (daily treatment) | Pyridostigmine |
| Reversing paralysis after surgery | Neostigmine |
| Alzheimer's disease | Donepezil, Rivastigmine, Galantamine |
| Atropine overdose | Physostigmine |
| Paralytic ileus / urinary retention | Neostigmine |
| Glaucoma | Echothiophate (historical) |
| Diagnosing myasthenia gravis | Edrophonium (historical) |
Give a long note of 12 to 15 marks on anticholinesterase in easy language with flow charts to the point exam ready answer
NORMAL SITUATION:
─────────────────────────────────────────────────────
Nerve ──► releases ACh ──► ACh acts on receptor
│
AChE breaks ACh down
│
Effect STOPS normally
─────────────────────────────────────────────────────
WITH ANTICHOLINESTERASE DRUG:
─────────────────────────────────────────────────────
Nerve ──► releases ACh ──► ACh acts on receptor
│
AChE is BLOCKED by drug
│
ACh is NOT broken down
│
ACh keeps accumulating
│
PROLONGED & EXAGGERATED EFFECTS
─────────────────────────────────────────────────────

ANTICHOLINESTERASE DRUGS
│
├── A. REVERSIBLE
│ │
│ ├── 1. Short-acting
│ │ • Edrophonium (10–20 min)
│ │
│ ├── 2. Intermediate-acting
│ │ • Physostigmine (30 min – 2 hrs) ← TERTIARY AMINE
│ │ • Neostigmine (30 min – 2 hrs) ← QUATERNARY AMINE
│ │ • Pyridostigmine (3–6 hrs) ← QUATERNARY AMINE
│ │ • Ambenonium
│ │
│ └── 3. Long-acting (used in Alzheimer's)
│ • Donepezil
│ • Rivastigmine
│ • Galantamine
│ • Tacrine (WITHDRAWN — hepatotoxic)
│
└── B. IRREVERSIBLE
Organophosphates:
• Echothiophate (eye drops — glaucoma)
• Parathion, Malathion (insecticides)
• Sarin, Soman, VX, Tabun (nerve agents)
ORGANOPHOSPHATE MECHANISM:
───────────────────────────────────────────────────────────
Organophosphate
│
▼
Covalently binds to SERINE-OH at active site of AChE
│
▼
AChE is permanently PHOSPHORYLATED → INACTIVE
│
▼
"AGING" occurs (loss of one alkyl group)
│
▼
Bond becomes ABSOLUTELY IRREVERSIBLE
(Even pralidoxime cannot break it after aging)
│
▼
New AChE must be synthesized (takes weeks)
───────────────────────────────────────────────────────────

Key point on Aging: Soman ages fastest (within seconds) → Pralidoxime is least effective against Soman.
S ── Salivation (excessive)
L ── Lacrimation (tearing)
U ── Urination (increased)
D ── Defecation / Diarrhea
G ── GI cramps
E ── Emesis (nausea/vomiting)
PLUS:
• Eye → Miosis (pin-point pupils) + spasm of accommodation
• Heart → Bradycardia + hypotension
• Lungs → Bronchoconstriction + increased secretions
• Skin → Diaphoresis (sweating)

Low dose → Muscle fasciculations, increased strength
High dose → Depolarizing block → Muscle PARALYSIS
(ganglionic stimulation can also cause tachycardia)
Mild → Anxiety, restlessness, dizziness
Severe → Seizures / convulsions → Coma → Respiratory depression
Exam tip: Quaternary amines (neostigmine, pyridostigmine, edrophonium) CANNOT cross BBB → no CNS effects. Tertiary amines (physostigmine) and organophosphates CAN cross BBB → CNS effects occur.
Remember: Physostigmine = Only reversible AChE inhibitor that enters the brain = Used for atropine OD
| Drug | Special Feature |
|---|---|
| Donepezil | t½ = 70 hrs, once daily, used in all stages of AD |
| Rivastigmine | Inhibits AChE + BuChE; also used in Parkinson's dementia; patch available |
| Galantamine | Also allosteric nicotinic receptor modulator |
| Tacrine | FIRST agent — WITHDRAWN due to hepatotoxicity |
ANTICHOLINESTERASE DRUGS — USES
│
├── Myasthenia Gravis
│ ├── Chronic daily treatment ──► PYRIDOSTIGMINE (oral)
│ ├── Acute / post-op ──────────► NEOSTIGMINE
│ └── Diagnosis (historical) ───► EDROPHONIUM
│
├── Post-surgery NMJ Reversal ────────► NEOSTIGMINE + Atropine
│
├── Paralytic Ileus / Urinary Retention ──► NEOSTIGMINE
│
├── Alzheimer's Disease ──────────────► DONEPEZIL / RIVASTIGMINE / GALANTAMINE
│
├── Atropine/Anticholinergic Poisoning ──► PHYSOSTIGMINE (crosses BBB)
│
└── Glaucoma (historical) ────────────► ECHOTHIOPHATE (mostly replaced)
CHOLINERGIC CRISIS
│
├── MUSCARINIC (SLUDGE)
│ Salivation, Lacrimation, Urination,
│ Defecation, GI cramps, Emesis
│ + Miosis, Bradycardia,
│ + Bronchoconstriction + secretions
│ + Diaphoresis, Hypotension
│
├── NICOTINIC
│ Muscle fasciculations → Weakness → PARALYSIS
│ Tachycardia (ganglionic)
│
└── CNS
Anxiety → Seizures → Coma
Central respiratory depression
⚠️ DEATH = RESPIRATORY FAILURE
(Bronchoconstriction + Paralysis of breathing muscles
+ CNS depression → can't breathe)
STEP 1: SUPPORTIVE CARE
Clear airway, O₂, mechanical ventilation
│
▼
STEP 2: ATROPINE (High doses IV)
Blocks muscarinic effects
Opens airways, stops secretions,
raises heart rate
Given until "atropinization"
(dry mouth, tachycardia = endpoint)
⚠️ Does NOT reverse nicotinic or CNS effects
│
▼
STEP 3: PRALIDOXIME (2-PAM)
Reactivates AChE
Must give EARLY (before aging)
Reverses peripheral muscarinic + nicotinic effects
⚠️ Does NOT cross BBB
⚠️ Useless after aging occurs
⚠️ Cannot reverse carbamate (neostigmine) toxicity
│
▼
STEP 4: DIAZEPAM
Controls persistent seizures
| Feature | Physostigmine | Neostigmine |
|---|---|---|
| Type | Tertiary amine | Quaternary amine |
| Source | Natural (Calabar bean) | Synthetic |
| Crosses BBB? | YES | NO |
| GI Absorption | Good | Poor |
| CNS effects | Yes | No |
| Skeletal muscle effect | Moderate | Greater |
| Used for atropine OD? | YES | No |
| Used for NMJ reversal? | No | YES |
| Used in myasthenia gravis? | Not preferred | YES |
★ "Anticholinesterase drugs are indirect cholinomimetics — they increase ACh by blocking its breakdown."
★ "Physostigmine is the only reversible AChE inhibitor that crosses BBB — used in atropine poisoning."
★ "Neostigmine has greater effect on skeletal muscle than physostigmine."
★ "Pyridostigmine is preferred over neostigmine for long-term myasthenia gravis because it lasts longer (3–6 hrs)."
★ "Organophosphates cause irreversible inhibition by phosphorylating AChE."
★ "Aging = loss of alkyl group from phosphorylated AChE = absolutely irreversible = pralidoxime won't work."
★ "Soman ages fastest (seconds) → pralidoxime least effective against soman."
★ "Death in organophosphate poisoning = respiratory failure."
★ "Treatment of OP poisoning = Atropine (muscarinic) + Pralidoxime (reactivates AChE) + Diazepam (seizures)."
★ "Tacrine = first Alzheimer's drug = WITHDRAWN due to hepatotoxicity."
★ "Pralidoxime does not cross BBB — cannot reverse CNS effects of OP poisoning."